| 5 | 1/1 | 返回列表 |
| 查看: 5307 | 回復: 12 | ||
| 【懸賞金幣】回答本帖問題,作者WORKDAY將贈送您 5 個金幣 | ||
| 當前只顯示滿足指定條件的回帖,點擊這里查看本話題的所有回帖 | ||
[求助]
審稿人意見major revision,改后重投悲劇,如何申訴? 已有7人參與
|
||
|
各位同僚,在投稿BMC nephrology 之后兩位審稿人給的意見都是major revision,后責編回信reject但是提出:如果可以point by point回復審稿意見,歡迎我們resubmit a new manuscript,按照責編的要求一一修改后resubmit,可是一個月后責編回信拒掉了,也沒送審。我勒個去,這種情況有經(jīng)驗的同志指導一下,我是該申訴呢還是該申訴呢?責編為啥沒送審直接拒掉了?下附信件內(nèi)容: 第一次責編回信的內(nèi)容:Peer review of your manuscript is now complete and, based on the reports, I am sorry to say that we cannot consider the manuscript for publication at this time. We think it may be possible to revise your manuscript to address these comments but that this would require longer than our standard revision period. However, we are willing to consider your manuscript further once all the concerns have been addressed. Therefore, if you are able to address all of these concerns, please do submit a new manuscript to BMC Nephrology. If you are able to do this, a full covering letter, explaining the revisions made, should accompany the submission. Their reports, together with any other comments, are below. Please also take a moment to check our website at https://www.editorialmanager.com/bnep/ for any additional comments that were saved as attachments. Please note that as BMC Nephrology has a policy of open peer review, you will be able to see the names of the reviewers. If you can address all of these concerns raised, please do submit a new manuscript to https://www.editorialmanager.com/bnep/. We request that a point-by-point response letter accompanies your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing what amendments have been made to the manuscript text and where these can be found (e.g. Methods section, line 12, page 5). Please also ensure that all changes to the manuscript are indicated in the text by highlighting or using track changes. If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision. Please note that this decision applies across the BMC-series journals (https://www.biomedcentral.com/authors/bmcseries#journallist). Therefore, if you were to submit your revised manuscript to another journal within the BMC series, your submission should also be accompanied by a full covering letter. I wish you every success with your research and hope that you will consider us again in the f 第二次責編回信內(nèi)容: Editor\'s comments: The paper is useful but not of practical assistance. A sudden progression of renal dysfunction in patients with CKD already on a nephrotoxic chronic medication will always require a search for any reversible etiology. |
至尊木蟲 (文壇精英)
木蟲 (正式寫手)
木蟲 (著名寫手)
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研]
材料學碩,求調(diào)劑
6+3
|
糖葫蘆888ll 2026-03-22 | 6/300 |
|
|---|---|---|---|---|
|
[考研] 0856材料專碩353求調(diào)劑 +5 | NIFFFfff 2026-03-20 | 5/250 |
|
|
[考研] 一志愿華東理工大學081700,初試分數(shù)271 +5 | kotoko_ik 2026-03-23 | 6/300 |
|
|
[考研] 327求調(diào)劑 +5 | prayer13 2026-03-23 | 5/250 |
|
|
[考研] 384求調(diào)劑 +3 | 子系博 2026-03-22 | 6/300 |
|
|
[考研] 一志愿陜師大生物學071000,298分,求調(diào)劑 +3 | SYA! 2026-03-23 | 3/150 |
|
|
[考研] 333求調(diào)劑 +3 | ALULU4408 2026-03-23 | 3/150 |
|
|
[考研] 上海電力大學材料防護與新材料重點實驗室招收調(diào)劑研究生(材料、化學、電化學,環(huán)境) +3 | 我愛學電池 2026-03-23 | 3/150 |
|
|
[考研] 328求調(diào)劑 +4 | LHHL66 2026-03-23 | 4/200 |
|
|
[考研]
求調(diào)劑材料學碩080500,總分289分
5+3
|
@taotao 2026-03-19 | 21/1050 |
|
|
[考研] 311求調(diào)劑 +3 | 26研0 2026-03-20 | 3/150 |
|
|
[考研] 廣西大學材料導師推薦 +3 | 夏夏夏小正 2026-03-17 | 5/250 |
|
|
[考研] 材料與化工(0856)304求B區(qū)調(diào)劑 +3 | 邱gl 2026-03-20 | 7/350 |
|
|
[考研] 求調(diào)劑 +4 | 要好好無聊 2026-03-21 | 4/200 |
|
|
[考研] 0703化學調(diào)劑 +4 | 妮妮ninicgb 2026-03-21 | 4/200 |
|
|
[考研] 297求調(diào)劑 +3 | 喜歡還是不甘心 2026-03-20 | 3/150 |
|
|
[考研] 22 350 本科985求調(diào)劑,求老登收留 +3 | 李軼男003 2026-03-20 | 3/150 |
|
|
[考研] 一志愿華中科技大學,080502,354分求調(diào)劑 +5 | 守候夕陽CF 2026-03-18 | 5/250 |
|
|
[考研] 288求調(diào)劑 +16 | 于海海海海 2026-03-19 | 16/800 |
|
|
[考研] 求調(diào)劑 +3 | @taotao 2026-03-20 | 3/150 |
|